Latest News

UHN Launches Behind the Breakthrough Podcast

October 09, 2019 /in Latest News

Behind the Breakthrough: ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ A podcast about the people behind the world-leading research at UHN

UHN Podcast Behind the Breakthrough Cover

UHN is excited to launch a new podcast series called "Behind the Breakthrough". Featuring interviews with scientists from across UHN, the podcast reveals the motivation behind their pursuit of answers to important questions—what is the cure for Alzheimer disease? How can we help prevent the elderly from falling? Will stem cells regenerate damaged hearts? How does cancer start?

Episodes present intimate, one-on-one conversations with UHN scientists...

Read More

UHN Spin-off Technology, Moleculight's i:X, is Featured at the Largest Canadian Wound Care Conference

October 07, 2019 /in Latest News

Results from Clinical Studies using MolecuLight i:X® Fluorescence Imaging System
 Featured Prominently at the Wounds Canada 2019 Annual Conference

October 4, 2019

Point-of-Care Fluorescence Imaging for Chronic Wounds and its Significant Clinical Benefits are Featured at the Largest Canadian Wound Care Conference in 5 Clinical Talks and Posters

NIAGARA FALLS, Canada and TORONTO, Canada – (October 4, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, and its i:X point-of-care fluorescence imaging device are featured prominently at the Wounds Canada 2019 Annual Conference. The conference, which is the...

Read More

UHN Research's Gordon Keller Receives Ogawa-Yamanaka Stem Cell Prize

September 05, 2019 /in Latest News

World-renowned stem cell scientist Gordon Keller, PhD, is the recipient of the 2019 Ogawa-Yamanaka Stem Cell Prize awarded by the Gladstone Institutes for his work with pluripotent stem cells.

Dr. Keller is the Director of the McEwen Stem Cell Institute at the University Health Network, Senior Scientist at Princess Margaret Cancer Centre and Professor in the department of medical biophysics at the University of Toronto. He was recognized for his contributions to efficient lineage-specific differentiation of human pluripotent stem cells into a myriad of cell types, enabling disease modeling and...

Read More

photonamic Acquires Oncology Business from UHN Spin-off MolecuLight

August 14, 2019 /in Latest News

          

photonamic GmbH & Co. KG (Germany) Acquires the Oncology Business from MolecuLight Inc. (Canada)

August 14th, 2019  photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; CEO: Ulrich Kosciessa, Ph.D.) (“photonamic”), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku,Tokyo; Representative Director, President and CEO: Yoshitaka Kitao) is engaged in the business of pharmaceutical development of 5-aminolevulinic acid (“5-ALA”) (*) hereby announces the acquisition of the Oncology Business of MolecuLight Inc. (Head office: Toronto, Canada; CEO: Anil Amlani) (“MolecuLight”), through its newly...

Read More

TDC Launches Alliance Management at UHN

August 13, 2019 /in Latest News

Christina von Gemmingen, launches Alliance Management for UHN as Licensing Professional/Alliance Manager at TDC

 

Technology Development and Commercialization is pleased to announce the arrival of Christina von Gemmingen, who launches the function of Alliance Management for UHN as Licensing Professional/Alliance Manager at TDC.

The launch of an Alliance Management function at TDC brings a new level of sophistication to the management of partner relationships between industry and our research community. In this role, Christina will maintain a strategic overview of contracts with our industry partners, and help ensure the success of these partnerships by aligning internally and externally with stakeholders on all...

Read More

UHN Spin-out BlueRock Therapeutics Aquired by Bayer in US$1 Billion Deal

August 08, 2019 /in Latest News
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
– Implied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer
– Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year
– BlueRock Therapeutics to continue to operate as an independent company 

Berlin/Cambridge, Mass., Aug. 8, 2019 – Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform....

Read More

UHN's Dr. Rob Rottapel’s Research Tools Reach the Global Research Community

August 08, 2019 /in Latest News

UHN is pleased to announce a successful licensing deal with EMD Millipore which will provide for UHN Princess Margaret Cancer Centre Senior Scientist Rob Rottapel’s research tools to the global research community. The research tools can be found at:

MABC1096, Anti-GEF-H1, clone 3C5       

http://www.emdmillipore.com/US/en/product/Anti-GEF-H1-Antibody-clone-3C5,MM_NF-MABC1096-25UG

http://www.emdmillipore.com/US/en/product/Anti-GEF-H1-Antibody-clone-3C5,MM_NF-MABC1096-100UG

 

MABC1097, Anti-GEF-H1, clone 14B11

...

Read More

Princess Margaret Cancer Centre Innovation Acceleration Fund Announces New Recipients of Funding in Support of Early Stage Technology Development

June 20, 2019 /in Latest News

The Princess Margaret Cancer Foundation’s Innovation Accelerator Fund (IAF) Leadership Board has announced the first three funded projects of 2019.  The IAF was established by The Princess Margaret Cancer Foundation in collaboration with University Health Network’s Technology Development and Commercialization Office in January 2016 to help investigators at the Princess Margaret Cancer Centre accelerate their early-stage research discoveries towards commercialization.  The fund provides a maximum of $250,000 per proposal, helping to take novel technologies from bench-to-bedside. The three selected projects of this round include:

 

Preclinical Testing of Novel TCR-based Treatment for Cancer

Dr. Naoto Hirano, a Senior Scientist at the Princess Margaret Cancer Centre, was selected for an additional round of IAF funding to support the...

Read More

Drs. Shaf Keshavjee and Marcelo Cypel named joint UHN Inventor of the Year

June 13, 2019 /in Latest News

Drs. Shaf Keshavjee (L) and Marcelo Cypel have taken their invention through pre-clinical and clinical trials and achieved government approval, making it a fully-approved and funded clinical therapy. (Photo: UHN StRIDe Team)

Drs. Shaf Keshavjee and Marcelo Cypel were recognized yesterday as the joint-winners of UHN's 2018 Inventor of the Year by the UHN Technology Development & Commercialization Office (TDC). 

Each year, UHN's TDC awards and celebrates a UHN inventor or inventors who illustrate noteworthy excellence through inventiveness in research, critical contributions and commercial successes impacting patients and their quality of life.

Drs....

Read More

UHN Helping Make Toronto a Leader in Healthcare Innovation

May 28, 2019 /in Latest News
 
Thanks to JLABS for highlighting some of UHN's star researchers and their role in making Toronto a biotech destination!

Magic mix: Three ingredients that make Toronto a leader in healthcare innovation

By Allan Miranda, Head, JLABS Canada  May 23, 2019

Toronto, Ontario, Canada is becoming the next big technology hub for large global tech companies. From Google to Facebook to Uber, this city has attracted the world’s biggest tech companies to set up shop. In turn, this has attracted many new startups, including those in health care who are starting to call Toronto their home.

Johnson & Johnson Innovation – JLABS (JLABS @ Toronto) is one of Canada’s premier healthcare incubators. We are home to 50+ resident companies that are aiming to make advancements and developing new technologies...

Read More

LAB150 Innovation Award awarded to UHN's Brian Wu at Krembil Research Day

May 28, 2019 /in Latest News

LAB150 is a drug development collaboration between MaRS Innovation and a German-based CRO, Evotec SE, developed to accelerate Toronto’s academic research into market-ready products. With a combined multi-million-dollar financial commitment by MaRS Innovation and Evotec SE, this recently formed partnership aims to accelerate the development and commercialization of therapeutically focused programs and technologies with award amounts up to 400k USD.

LAB150 likes to recognize the community’s outstanding researchers committed to translating their academic research into novel therapeutic approaches that will ultimately improve patient care. As such, LAB150 was pleased to sponsor the “LAB150 Innovation Award” for UHN's Krembil Research Day. This award was presented to Krembil's Brian Wu for his work on Ephrin B2 Signaling in the Development of Pulmonary Fibrosis, who was the top-...

Read More

Takara Bio Inc. Licences UHN's New Generation CAR Gene Therapy

May 07, 2019 /in Latest News

Takara Bio to Acquire an Exclusive License to Use Patent Technology Relating to New Generation CAR Gene Therapy

Kusatsu/Shiga, Japan — April 26, 2019 – Takara Bio Inc. (Takara Bio) announces that it has entered into a worldwide license agreement with University Health Network in Canada*1  as of April 23, 2019, under which Takara Bio exclusively uses the patent technology relating to a new generation of CAR (Chimeric antigen receptor)*2 gene therapy. Takara Bio will develop the novel CAR gene therapy by leveraging the licensed technology, in cooperation with a group led by the patent inventor, Dr. Naoto Hirano, Associate Director for Research, Tumor Immunotherapy Program, Senior Scientist, Princess Margaret Cancer Centre / Professor of Medicine, Department of Immunology, University of Toronto (Toronto, Ontario, Canada).

In CAR...

Read More

UHN welcomes KITE, a new venture dedicated to rehabilitation research, science and commercialization

January 31, 2019 /in Latest News

UHN execs at KITE launch

On hand at TRI Research Day to introduce the change to staff and guests were: (L to R): Dr. Mark Bayley, Physiatrist in Chief & Medical Program Director, Toronto Rehab, Dr. Milos Popovic, Research Director, Toronto Rehab, Gillian Howard, VP, Public Affairs and Communications, UHN, Dr. Kevin Smith, President & CEO, UHN, Dr. Brad Wouters, EVP, Science and Research, UHN, and Dr. Geoff Fernie, former TRI Research Director. (Photo: UHN)

UHN is unveiling a new research institute designed to take the science of rehabilitation to new heights.   

Based at Toronto Rehab, the new institute, which will be known as KITE...

Read More

McEwen Stem Cell Institute Launched

December 07, 2018 /in Latest News

Announced on Dec 7, 2018

New Institute will accelerate work in regenerative medicine to help create new therapies.

   

On December 6, 2018, University Health Network (UHN) announced the creation of the McEwen Stem Cell Institute. The sixth institute within its research community, the McEwen Institute is focused on stem cell research and the promise of regenerative medicine and cell therapies.

Formerly the McEwen Centre for Regenerative Medicine, the evolution to the McEwen Stem Cell Institute signals the progress of the research since it was first formed in 2007. In collaboration with research institutions, clinical programs at UHN, and supporters from around the globe, investigators within...

Read More

UHN Remains Canada's Top Research Hospital in 2018!

November 15, 2018 /in Latest News

UHN buildings

Research Infosource Inc. list of Canada’s Top 40 Research Hospitals for 2018 shows research spending at the country’s leading research hospitals, hospital networks and health authorities rose 4.1 per cent to $2.65 billion in fiscal 2017, with UHN atop the list with $350.1 million. (Graphic: UHN)

​​UHN is once again ranked first on Canada's Top 40 Research Hospitals list for 2018.  

The list of top research hospitals across the country is compiled annually by Research Infosource Inc. 

UHN has appeared in the top position of the list every year since the rankings began in 2011.  

UHN's research expenditures for the 2017 fiscal year were $350.1 million, representing 17.3 per...

Read More

UHN's Dr. Sivak Snares the MaRS Innovation-Lab150/Evotec Award For Treating Glaucoma.

October 10, 2018 /in Latest News

Dr. Jeremy Sivak, Senior Scientist at the University Health Network (UHN)'s Krembil Research Institute snares the MaRS Innovation-LAB150/Evotec partnership award - the 1st ever at UHN and the 2nd ever under the partnership.

Dr. Sivak's project aims to develop a novel therapeutic approach to treat glaucoma, which is an irreversible neurodegenerative condition of the optic nerve; left untreated it can lead to blindness.  Glaucoma affects 1.9% of the population over 40 years of age and it is the leading cause of permanent blindness with over 70 million people affect worldwide.  

Dr. Sivak's team and collaborating scientists from the University of California at Berkeley (UC Berkeley) discovered a lipoxin with neuroprotective properties that has illustrated efficacy in preclinical glaucoma models.  With the award, Dr. Sivak will now team up with Dr. Mark Reed, who is a...

Read More

AVROBIO - UHN's Gene Therapy Start-up Announces Positive Phase 1 and 2 Clinical Data

October 01, 2018 /in Latest News

AVROBIO Inc, a UHN gene therapy start-up company, that recently IPO'ed on the NASDAQ (ticker symbol: "AVRO"), announced today that the initial clinical data for AVR-RD-01 gene therapy for AGA enzyme replacement in Fabry Disease patients were positive in both the Phase 1 and Phase II studies.

Read the full press release here: http://investors.avrobio.com/news-releases/news-release-details/avrobio-announces-updated-clinical-data-avr-rd-01-gene-therapy

 

 

 

Acumyn - UHN Spin-off Acquired

September 25, 2018 /in Latest News

Radiation therapy management software company Acumyn Inc. has been purchased by Elekta.

Acumyn Inc. was originally created by UHN in 2014 to commercialize AQUA radiation therapy management software.

 

A University Health Network spin-off company known as Acumyn Inc. was recently acquired by global radiotherapy giant Elekta.

Acumyn was created by UHN’s Technology Development and Commercialization (TDC) office to commercialize AQUATM, a software platform developed at Princess Margaret by a team led by Dr. Daniel...

Read More

UHN's start-up MolecuLight® Inc receives FDA De Novo clearance - Readies to enter the US wound care market

August 14, 2018 /in Latest News

 

Toronto-based, University Health Network (UHN) start-up company, MolecuLight® Inc. announced today that it has achieved a key regulatory milestone by receiving FDA's De Novo clearance for a first-of-its-kind handheld fluorescence imaging device, the MolecuLight i:X.

The MolecuLight i:X device captures and documents digital fluorescence information from wounds and tissue surrounding the wound site with real time videos and still images.  This point-of-care device has been optimized to be portable, compact, and eliminates the use of contrast agents. 

MolecuLight® Inc., will now be able to provide the MolecuLight i:X as a prescription-use only point-of-care imaging device to clinicians in the USA.  In turn...

Read More

AVROBIO IPO'S on NASDAQ - Raises over US$100 Million

July 30, 2018 /in Latest News

The University of Health Network (UHN)'s spinout - AVROBIO Inc - a recently public gene therapy biotechnology company raised over US$100 Million in it's initial public offering (IPO) on the NASDAQ stock exchange.  Less than one month of going public, AVROBIO it trading with a market cap of greater than US$651 Million.  AVROBIO is trading on the NASDAQ under the ticker symbol "AVRO".

AVROBIO, founded on the research done by Dr. Christopher Paige (UHN Senior Scientist;...

Read More